Keywords: USA, Bristol-Myers Squibb, Belatacept, Kidney transplant, Complete response letter

US FDA delays approval of Bristol-Myers Squibb’s belatacept for kidney transplant patients

Article | 04 May 2010

Print This

The US Food and Drug Administration has issued a complete response letter regarding Bristol-Myers Squibb’s Biologics License Application for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in